American Journal of Kidney Diseases
Volume 55, Issue 2 , Pages 205-208 , February 2010

World Kidney Day 2010: Diabetic Kidney Disease—Act Now or Pay Later

  • Robert C. Atkins, MD, PhD, DSc

      Affiliations

    • Monash Medical Centre, Victoria, Australia
    • ,
  • Paul Zimmet, MD, PhD

      Affiliations

    • Baker IDI Heart and Diabetes Institute, Victoria, Australia

References 

  1. International Diabetes Federation and International Society of Nephrology. Diabetes and kidney disease: time to act. http://www.idf.org/webdata/docs/Guide_Diabetes_Kidney.pdfAccessed November 30, 2009
  2. Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–787
  3. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–1431
  4. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–1688
  5. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In:  Gan D editors. Diabetes Atlas. 3rd ed.. Brussels, Belgium: International Diabetes Federation; 2006;p. 15–109
  6. Reutens AT, Prentice L, Atkins R. The Epidemiology of Diabetic Kidney Disease. In:  Ekoé J,  Rewers M,  Williams R,  Zimmet P editor. The Epidemiology of Diabetes Mellitus. 2nd ed.. Chichester, United Kingdom: John Wiley & Sons Ltd; 2008;p. 499–518
  7. US Renal Data System. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;p. 239–254
  8. Appendix II. In:  McDonald S,  Excell L,  Livingston B editor. ANZDATA Registry Report 2008. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry; 2008;p. 1–97
  9. Yamagata K, Iseki K, Nitta K, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12(1):1–8
  10. Lysaght M. Maintenance dialysis population dynamics: current trends and long term implications. J Am Soc Nephrol. 2002;13(suppl 1):S37–S40
  11. Adler AL, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–232
  12. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holamn RR UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832–1839
  13. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69(11):2057–2063
  14. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–1821
  15. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25(5):829–834
  16. White SL, Polkinghorne KR, Cass A, Shaw J, Atkins RC, Chadban SJ. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust. 2008;188(4):204–208
  17. Whaley-Connell A, Sowers JR, McCullough PA, et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009;53(4):S11–S21(suppl 4)
  18. Thomas M, Viberti G, Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point?. Nat Clin Pract Nephrol. 2008;4(1):2–3
  19. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
  20. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?. Diabet Med. 2008;25(suppl 2):25–29
  21. Gaede P, Lund-Andersen H, Parving HH, Pedersen O, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591
  22. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840
  23. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
  24. Zoungas S, de Galan BE, Ninomiya T, et al. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care. 2009;32(11):2068–2074
  25. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–1951
  26. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878
  27. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med. 2001;345(12):851–860
  28. Burney B, Kalaitzidis R, Bakris G. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2009;18(2):107–111
  29. Atkins R, Perico N, Codreanu I, Peng L, Remuzzi G ISN COMGAN Research Committee. Program for Detection and Management of Chronic Kidney Disease, Hypertension, Diabetes and Cardiovascular Disease in Developing Countries. http://www.nature.com/isn/education/guidelines/isn/pdf/ed_051027_2x1.pdfAccessed November 30, 2009

 This article is adapted and reprinted with permission of the authors. It was previously presented online by the authors at multiple websites, including www.worldkidneyday.org.

 Reprint requests to Marie-Agnes Cederborg, World Kidney Day Project Team. E-mail: Marie-Agnes.Cederborg@interel.eu

PII: S0272-6386(09)01570-4

doi: 10.1053/j.ajkd.2009.12.001

American Journal of Kidney Diseases
Volume 55, Issue 2 , Pages 205-208 , February 2010

Article Tools